Home LiteratureArticle Details
PMID: 8274151 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Structural and metabolic requirements for activators of the peroxisome proliferator-activated receptor.

Biochemical pharmacology ·Vol. 46 ·No. 12 ·1993-12-14 ·Pages 2177-84

Göttlicher M, Demoz A, Svensson D, Tollet P, Berge RK, Gustafsson JA

Abstract

Fatty acids have recently been demonstrated to activate peroxisome proliferator-activated receptors (PPARs) but specific structural requirements of fatty acids to produce this response have not yet been determined. Importantly, it has hitherto not been possible to show specific binding of these compounds to PPAR. To test whether a common PPAR binding metabolite might be formed, we tested the effects of long-chain omega-3 polyunsaturated fatty acids, differentially beta-oxidizable fatty acids and inhibitors of fatty acid metabolism. We determined the activation of a reporter gene by a chimaeric receptor encompassing the DNA binding domain of the glucocorticoid receptor and the ligand binding domain of PPAR. The omega-3 unsaturated fatty acids were slightly more potent PPAR activators in vitro than saturated fatty acids. The peroxisomal proliferation-inducing, non-beta-oxidizable, tetradecylthioacetic acid activated PPAR to the same extent as the strong peroxisomal proliferator WY 14,643, whereas the homologous beta-oxidizable tetradecylthiopropionic acid was only as potent as a non-substituted fatty acid. Cyclooxygenase inhibitors, radical scavengers or cytochrome P450 inhibitors did not affect activation of PPAR. In conclusion, beta-oxidation is apparently not required for the formation of the PPAR-activating molecule and this moiety might be a fatty acid, its ester with CoA, or a further derivative of the activated fatty acid prior to beta-oxidation of the acyl-CoA ester. These data should aid understanding of signal transduction via PPAR and the identification of a receptor ligand.

MeSH Terms
Animals Chimera Cyclooxygenase Inhibitors/pharmacology Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Enzyme System/biosynthesis,metabolism Fatty Acids/chemistry,pharmacology Fatty Acids, Omega-3/pharmacology Free Radical Scavengers Liver/cytology,drug effects,metabolism Male Microbodies/drug effects,metabolism Oxidation-Reduction Rats Rats, Wistar Receptors, Cytoplasmic and Nuclear/drug effects,genetics Receptors, Glucocorticoid/genetics Serum Albumin, Bovine/pharmacology Sulfur Transcription Factors/drug effects,genetics
Chemicals
Cyclooxygenase Inhibitors Cytochrome P-450 Enzyme Inhibitors Fatty Acids Fatty Acids, Omega-3 Free Radical Scavengers Receptors, Cytoplasmic and Nuclear Receptors, Glucocorticoid Transcription Factors Serum Albumin, Bovine Sulfur Cytochrome P-450 Enzyme System
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Göttlicher M
Department of Medical Nutrition, Karolinska Institute, Huddinge Hospital, NOVUM, Sweden.
Demoz A
Svensson D
Tollet P
Berge R K
Gustafsson J A
Article Info
Journal
Biochemical pharmacology
Abbr.
Biochem Pharmacol
ISSN
0006-2952
Published
1993-12-14
Pages
2177-84
Language
English
Region
England
NLM ID
0101032
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com